BIOMAT Database Logo BIOMAT Database Logo

Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. 1995

C H Bangma, and HOP WCJ, and F H Schröder
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands.

OBJECTIVE The contribution of serial prostate specific antigen (PSA) determinations was studied to obtain better understanding of the natural history of clinically confined prostate carcinoma. METHODS Serial PSA determinations in 29 patients with untreated confined prostate carcinoma were correlated to the clinical course for a mean of 39 months. RESULTS Disease progressed locally in 13 patients after a mean of 31 months. Metastatic progression was not observed. Neither grade, stage, PSA changes nor initial PSA showed significant differences with respect to interval of progression between patients with and without progression. CONCLUSIONS PSA does not parallel clinical progression in patients selected for watchful waiting.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein

Related Publications

C H Bangma, and HOP WCJ, and F H Schröder
Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
January 1989, European urology,
C H Bangma, and HOP WCJ, and F H Schröder
[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma].
November 1996, Schweizerische medizinische Wochenschrift,
C H Bangma, and HOP WCJ, and F H Schröder
Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy.
July 1992, Radiology,
C H Bangma, and HOP WCJ, and F H Schröder
Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
July 2001, The Journal of urology,
C H Bangma, and HOP WCJ, and F H Schröder
Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
January 1998, Cancer,
C H Bangma, and HOP WCJ, and F H Schröder
Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma.
January 1995, International urology and nephrology,
C H Bangma, and HOP WCJ, and F H Schröder
Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group.
December 1995, The Journal of urology,
C H Bangma, and HOP WCJ, and F H Schröder
Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades.
April 2011, Urology,
C H Bangma, and HOP WCJ, and F H Schröder
The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
March 2001, Cancer,
C H Bangma, and HOP WCJ, and F H Schröder
The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
May 2000, Cancer,
Copied contents to your clipboard!